DUBLIN, April 2, 2018 /PRNewswire/ — Alkermes plc (Nasdaq: ALKS) today announced that it received a Refusal to File letter from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for ALKS 5461, a once-daily, oral…Original Article
Alkermes Receives Refusal to File Letter From FDA for ALKS 5461
